Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of Chronic Obstructive Pulmonary Disease (COPD) and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown. The main objective of the study is to analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients with different stages of COPD compared to control subjects.

Official Title
-----------------
Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged more than 40 yr Patient needed a thoracic surgery such as lobectomy for cancer or lung transplantation or lung reduction volume surgery. COPD group: diagnostic of COPD and differentiation of the stage from 1 to 4 according to the GOLD guidelines. Control group: subjects with normal lung function testing and no chronic symptoms (cough or expectoration). Subjects will be separated in 2 groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex. with a written informed consent Exclusion Criteria: Subject without any social security or health insurance Asthma, lung fibrosis or idiopathic pulmonary hypertension Chronic viral infections (hepatitis, HIV) Pregnant woman or breastfeeding Subject included for cancer surgery with a Pn0 diagnosis not confirmed after the intervention.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD<br>15 patients with COPD from 1 to 4 according to the GOLD 2011 | |
| Non smoker Control<br>15 patients without COPD and no smoking history | |
| Smoker Control<br>15 patients without COPD but a smoking history | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increased number of peri-bronchial and blood circulating fibrocytes gradually in each stages of COPD and compared to control subjects. |  | Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterization of fibrocytes: expression of chemokines receptors, Toll Like Receptors, HLA class II |  | Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0) | 
| Correlation between lung attenuation and the number of fibrocytes |  | Assessed one year after inclusion visit (i.e. surgery date =Day 0) | 
| Correlation between plethysmography and the number of fibrocytes. |  | Assessed one year after inclusion visit (i.e. surgery date = Day 0) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Obstructive Pulmonary Disease, Fibrosis, Fibroblast, Lung attenuation, Pletysmography